Literature DB >> 35633434

Non-cardiovascular medication and readmission for heart failure: an observational cohort study.

Willemien J Kruik-Kollöffel1, Enriqueta Vallejo-Yagüe2, Kris L L Movig3, Gerard C M Linssen4, Edith M Heintjes5, Job van der Palen2,6.   

Abstract

Background Among heart failure (HF) patients, hospital readmissions are a major concern. The medication taken by a patient may provide information on comorbidities and conditions and may be used as an indicator to identify populations at an increased risk of HF readmission. Aim This study explored the use of non-cardiovascular medication at hospital discharge from the first HF admission in search of indicators of high risk of readmission for HF. Method The study included 22,476 HF patients from the Dutch PHARMO Database Network at their first HF hospitalization. The data was divided into training and validation sets. A Cox regression model with demographics, date of first HF hospital admission and non-cardiovascular medication present at discharge, adjusted for cardiovascular medication, was developed in the training set and subsequently implemented in the validation set. Results The study included 22,476 patients, mean age 76.7 years (range 18-104) and median follow-up time 2.5 years (range 0-15.7 years). During the study period 6,725 (29.9%) patients were readmitted for HF, with a median time-to-readmission of 7 months (range 0-14.3 years). Non-cardiovascular medication associated with a high risk of readmission for HF were identified as indicators of high risk, with no implied causal relationship. Patients prescribed antigout medications presented a 25% increased risk of readmission (HR 1.25, 95%CI 1.09-1.45, P = 0.002). Patients using insulin had an 18% higher risk of readmission versus patients not using insulin (HR 1.18, 95%CI 1.06-1.32, P = 0.002), but not versus patients treated with other blood-glucose-lowering drugs. No association between the risk of readmission and NSAIDs use was observed. Conclusion The results suggest that diabetes is responsible for the higher HF-readmission risk observed in patients prescribed insulin. The observed risk in users of antigout medication should be further investigated. The absence of an association with the use of NSAIDs should be interpreted with caution.
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Keywords:  Diabetes; Epidemiology; Heart failure; Hospitalization; Medication; Readmission

Mesh:

Substances:

Year:  2022        PMID: 35633434     DOI: 10.1007/s11096-022-01418-3

Source DB:  PubMed          Journal:  Int J Clin Pharm


  24 in total

Review 1.  2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.

Authors:  Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Monica M Colvin; Mark H Drazner; Gerasimos S Filippatos; Gregg C Fonarow; Michael M Givertz; Steven M Hollenberg; JoAnn Lindenfeld; Frederick A Masoudi; Patrick E McBride; Pamela N Peterson; Lynne Warner Stevenson; Cheryl Westlake
Journal:  Circulation       Date:  2017-04-28       Impact factor: 29.690

2.  National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Guidelines for the Prevention, Detection, and Management of Heart Failure in Australia 2018.

Authors:  John J Atherton; Andrew Sindone; Carmine G De Pasquale; Andrea Driscoll; Peter S MacDonald; Ingrid Hopper; Peter M Kistler; Tom Briffa; James Wong; Walter Abhayaratna; Liza Thomas; Ralph Audehm; Phillip Newton; Joan O'Loughlin; Maree Branagan; Cia Connell
Journal:  Heart Lung Circ       Date:  2018-10       Impact factor: 2.975

3.  Rehospitalization for heart failure: predict or prevent?

Authors:  Akshay S Desai; Lynne W Stevenson
Journal:  Circulation       Date:  2012-07-24       Impact factor: 29.690

Review 4.  Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association.

Authors:  Robert L Page; Cindy L O'Bryant; Davy Cheng; Tristan J Dow; Bonnie Ky; C Michael Stein; Anne P Spencer; Robin J Trupp; JoAnn Lindenfeld
Journal:  Circulation       Date:  2016-07-11       Impact factor: 29.690

5.  Co-morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey.

Authors:  Vincent M van Deursen; Renato Urso; Cecile Laroche; Kevin Damman; Ulf Dahlström; Luigi Tavazzi; Aldo P Maggioni; Adriaan A Voors
Journal:  Eur J Heart Fail       Date:  2013-12-19       Impact factor: 15.534

Review 6.  Reframing the association and significance of co-morbidities in heart failure.

Authors:  Filippos Triposkiadis; Gregory Giamouzis; John Parissis; Randall C Starling; Harisios Boudoulas; John Skoularigis; Javed Butler; Gerasimos Filippatos
Journal:  Eur J Heart Fail       Date:  2016-06-30       Impact factor: 15.534

7.  The recurring problem of heart failure hospitalisations.

Authors:  Pardeep S Jhund
Journal:  Eur J Heart Fail       Date:  2020-01-11       Impact factor: 15.534

8.  2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.

Authors:  Theresa A McDonagh; Marco Metra; Marianna Adamo; Roy S Gardner; Andreas Baumbach; Michael Böhm; Haran Burri; Javed Butler; Jelena Čelutkienė; Ovidiu Chioncel; John G F Cleland; Andrew J S Coats; Maria G Crespo-Leiro; Dimitrios Farmakis; Martine Gilard; Stephane Heymans; Arno W Hoes; Tiny Jaarsma; Ewa A Jankowska; Mitja Lainscak; Carolyn S P Lam; Alexander R Lyon; John J V McMurray; Alexandre Mebazaa; Richard Mindham; Claudio Muneretto; Massimo Francesco Piepoli; Susanna Price; Giuseppe M C Rosano; Frank Ruschitzka; Anne Kathrine Skibelund
Journal:  Eur Heart J       Date:  2021-09-21       Impact factor: 29.983

9.  New opportunities for drug outcomes research in cancer patients: the linkage of the Eindhoven Cancer Registry and the PHARMO Record Linkage System.

Authors:  Myrthe P P van Herk-Sukel; Lonneke V van de Poll-Franse; Valery E P P Lemmens; Gerard Vreugdenhil; Johannes F M Pruijt; Jan Willem W Coebergh; Ron M C Herings
Journal:  Eur J Cancer       Date:  2009-10-05       Impact factor: 9.162

10.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.

Authors:  Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer
Journal:  Eur Heart J       Date:  2016-05-20       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.